Utility of HLA antibody testing in kidney transplantation

Journal of the American Society of Nephrology

Volumn 26, Issue 7, 2015, Pages 1489-1502

  Konvalinka, Ana ^a   Tinckam, Kathryn ^a,b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; EPITOPE; HLA ANTIBODY; HLA ANTIGEN;

ANTIBODY DETECTION; ANTIGEN BINDING; ANTIGEN STRUCTURE; CONFORMATIONAL TRANSITION; HUMAN; IMMUNOASSAY; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; REVIEW; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CELLULAR IMMUNITY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MALE; PHYSIOLOGY; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME; UTILIZATION;

FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROGNOSIS; RISK ASSESSMENT; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84934779526     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014080837     Document Type: Review

References (150)

1. Patel R, Terasaki PI: Significance of the positive crossmatch test in kidney transplantation. N Engl JMed 280: 735-739, 1969
2. Stiller CR, Sinclair NR, Abrahams S, Ulan RA, FungM,Wallace AC: Lymphocyte-dependent antibody and renal graft rejection. Lancet 1: 953-954, 1975
3. Iwaki Y,CookDJ, Terasaki PI, Lau M,Terashita GY, Danovitch G, Fine R, Ettenger R, Mendez R, Kavalich A. Flow cytometry crossmatching in human cadaver kidney transplantation. Transplant Proc 19: 764-766, 1987
4. Cook DJ, Terasaki PI, Iwaki Y, Terashita G, Takeda A, Fujikawa J, Lau M, Danovitch G, Rosenthal JT, Fine R. The flow cytometry crossmatch in kidney transplantation. Clin Transpl 1987: 409-414, 1987
5. Mahoney RJ, Ault KA, Given SR, Adams RJ, Breggia AC, Paris PA, Palomaki GE, Hitchcox SA, White BW, Himmelfarb J, Leeber DA. et al: The flow cytometric crossmatch and early renal transplant loss. Transplantation 49: 527-535, 1990
6. Kerman RH, Van Buren CT, Lewis RM, DeVera V, Baghdahsarian V, Gerolami K, Kahan BD: Improvedgraft survival for flowcytometry and antihuman globulin crossmatch-negative retransplant recipients. Transplantation 49: 52-56, 1990
7. Ogura K, Terasaki PI, Johnson C, Mendez R, Rosenthal JT, Ettenger R, Martin DC, Dainko E, Cohen L, Mackett T, Berne, T.; Barba, L.; Lieberman, E. The significance of a positive flow cytometry crossmatch test in primary kidney transplantation. Transplantation 56: 294-298, 1993
8. Karpinski M, Rush D, Jeffery J, Exner M, Regele H, Dancea S, Pochinco D, Birk P, Nickerson P: Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 12: 2807-2814, 2001
9. Bryan CF, Baier KA, Nelson PW, Luger AM, Martinez J, Pierce GE, Ross G, Shield CF 3rd, Warady BA, Aeder MI, Helling TS, Muruve N: Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching. Transplantation 66: 1827-1832, 1998
10. Gebel HM, Bray RA: Sensitization and sensitivity: Defining the unsensitized patient. Transplantation 69: 1370-1374, 2000
11. Zou Y, Stastny P, Süsal C, Döhler B, OpelzG: Antibodies against MICA antigens and kidney-transplant rejection.NEngl JMed357: 1293-1300, 2007
12. Dragun D,Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D,Mazak I, PlehmR, SchönemannC, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352: 558-569, 2005
13. Rodríguez PC, Arroyave IH, Mejía G, García LF: Detection of alloantibodies against non-HLA antigens in kidney transplantation by flow cytometry. Clin Transplant 14: 472-478, 2000
14. Sun Q, Cheng Z, Cheng D, Chen J, Ji S,Wen J, Zheng C, Liu Z: De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection. Kidney Int 79: 655-662, 2011
15. Cross DE, Greiner R, Whittier FC: Importance of the autocontrol crossmatch in human renal transplantation. Transplantation 21: 307-311, 1976
16. Ting A, Morris PJ: Renal transplantation and B-cell cross-matches with autoantibodies and alloantibodies. Lancet 2: 1095-1097, 1977
17. Ettenger RB, Jordan SC, Fine RN: Cadaver renal transplant outcome in recipients with autolymphocytotoxic antibodies. Transplantation 35: 429-431, 1983
18. Taylor CJ, Chapman JR, Ting A, Morris PJ: Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome. Transplantation 48: 953-958, 1989
19. Vaidya S, Ruth J: Contributions and clinical significance of IgM and autoantibodies in highly sensitized renal allograft recipients. Transplantation 47: 956-958, 1989
20. Bryan CF, Martinez J, Muruve N, Nelson PW, Pierce GE, Ross G, Shield CF, Warady BA, Aeder MI, Harrell KM, Helling TS, Luger AM: IgMantibodies identified by a DTT-ameliorated positive crossmatch do not influence renal graft outcome but the strength of the IgM lymphocytotoxicity is associated with DR phenotype. Clin Transplant 15[Suppl 6]: 28-35, 2001
21. Le Bas-Bernardet S, Hourmant M, Valentin N, Paitier C, Giral-Classe M, Curry S, Follea G, Soulillou JP, Bignon JD: Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 75: 477-482, 2003
22. PatelAM, Pancoska C,Mulgaonkar S,Weng FL: Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 7: 2371-2377, 2007
23. Bielmann D, Honger G, Lutz D, Mihatsch MJ, Steiger J, Schaub S: Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 7: 626-632, 2007
24. Taylor CJ, Kosmoliaptsis V, Summers DM, Bradley JA: Back to the future: Application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Hum Immunol 70: 563-568, 2009
25. Tinckam K: Histocompatibility methods. Transplant Rev (Orlando) 23: 80-93, 2009
26. Tait BD, Hudson F, Brewin G, Cantwell L, Holdsworth R: Solid phase HLA antibody detection technology-challenges in interpretation. TissueAntigens76: 87-95, 2010
27. Zachary AA, Kopchaliiska D, Jackson AM, Leffell MS: Immunogenetics and immunology in transplantation. Immunol Res 47: 232-239, 2010
28. Roelen DL, Doxiadis II, Claas FH: Detection and clinical relevance of donor specific HLA antibodies: A matter of debate. Transpl Int 25: 604-610, 2012
29. Zachary AA, Vega RM, Lucas DP, LeffellMS: HLA antibody detection and characterization by solid phase immunoassays: Methods and pitfalls. Methods Mol Biol 882: 289-308, 2012
30. Montgomery RA, Leffell MS, Zachary AA: Transplantation of the sensitized patient: Histocompatibility testing. Methods Mol Biol 1034: 117-125, 2013
31. Süsal C, Opelz G: Current role of human leukocyte antigen matching in kidney transplantation. Curr Opin Organ Transplant 18: 438-444, 2013
32. Haarberg KM, Tambur AR: Detection of donor-specific antibodies in kidney transplantation. Br Med Bull 110: 23-34, 2014
33. Bray RA, Nickerson PW, Kerman RH, Gebel HM: Evolution of HLA antibody detection: Technology emulating biology. Immunol Res 29: 41-54, 2004
34. Archdeacon P, Chan M, Neuland C, Velidedeoglu E, Meyer J, Tracy L, Cavaille-Coll M, Bala S, Hernandez A, Albrecht R: Summary of FDA antibody-mediated rejection workshop.AmJ Transplant 11: 896-906, 2011
35. Reed EF, Rao P, Zhang Z, Gebel H, Bray RA, Guleria I, Lunz J, Mohanakumar T, Nickerson P, Tambur AR, Zeevi A, Heeger PS, Gjertson D: Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant 13: 1859-1870, 2013
36. Zachary AA, Ratner LE, Graziani JA, Lucas DP, Delaney NL, Leffell MS: Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: II. Clinical relevance. Hum Immunol 62: 236-246, 2001
37. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI: Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 75: 43-49, 2003
38. Pei R, Wang G, Tarsitani C, Rojo S, Chen T, Takemura S, Liu A, Lee J: Simultaneous HLA Class I and Class II antibodies screening with flowcytometry. HumImmunol 59: 313-322, 1998
39. Pei R, Lee J, Chen T, Rojo S, Terasaki PI: Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol 60: 1293-1302, 1999
40. Zachary AA, Braun WE: Calculation of a predictive value for transplantation. Transplantation 39: 316-318, 1985
41. Canadian Blood Services: cPRA Calculator. Available at: http://www.pra-calculator.ca. Accessed July 4, 2014
42. UNOS: HLA Matching Antigen Equivalences. Appendix 3, Policy 3A, 2010. Available at: http://optn.transplant.hrsa.gov/ PoliciesandBylaws2/policies/pdfs/policy-14. pdf. Accessed July 4, 2014
43. Cecka JM, Kucheryavaya AY, Reinsmoen NL, Leffell MS: Calculated PRA: Initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 11: 719-724, 2011
44. Cecka JM: Calculated PRA (CPRA): The new measure of sensitization for transplant candidates. Am J Transplant 10: 26-29, 2010
45. Bray RA, Nolen JD, Larsen C, Pearson T, Newell KA, Kokko K, Guasch A, Tso P, Mendel JB, Gebel HM: Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant 6: 2307-2315, 2006
46. Taylor CJ, Kosmoliaptsis V, Sharples LD, Prezzi D, Morgan CH, Key T, Chaudhry AN, Amin I, ClatworthyMR, Butler AJ, Watson CJ, Bradley JA: Ten-year experience of selective omission of the pretransplant crossmatch test in deceased donor kidney transplantation. Transplantation 89: 185-193, 2010
47. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Frémeaux-Bacchi V, Méjean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana JP, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X: Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 369: 1215-1226, 2013
48. Schaub S, Hönger G, Koller MT, Liwski R, Amico P: Determinants of C1q binding in the single antigen bead assay. Transplantation 98: 387-393, 2014
49. Immucor Transplant Diagnostics Inc.: Manufacturer Class I LSA(TM) Product Worksheet. Available at: http://www.immucor. com/LIFECODES Documents/LC980-NEW.6-LIFECODESLSAClass IWorksheetLot 06164B-RUO (2015-05) New Nomenclature. pdf. Accessed July 4, 2014
50. Tait BD, Süsal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, Reed EF, Bray RA, Campbell P, Chapman JR, Coates PT, Colvin RB, Cozzi E, Doxiadis II, Fuggle SV, Gill J, Glotz D, Lachmann N, Mohanakumar T, Suciu-Foca N, Sumitran-Holgersson S, Tanabe K, Taylor CJ, Tyan DB, Webster A, Zeevi A, Opelz G: Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 95: 19-47, 2013
51. Schnaidt M, Weinstock C, Jurisic M, Schmid-Horch B, Ender A, Wernet D: HLA antibody specification using singleantigen beads-A technical solution for the prozone effect. Transplantation 92: 510-515, 2011
52. Weinstock C, Schnaidt M: The complementmediated prozone effect in the Luminex single-antigen bead assay and its impact on HLA antibody determination in patient sera. Int J Immunogenet 40: 171-177, 2013
53. Kosmoliaptsis V, Bradley JA, Peacock S, Chaudhry AN, Taylor CJ: Detection of immunoglobulin G human leukocyte antigenspecific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulinMhuman leukocyte antigen-specific alloantibodies. Transplantation 87: 813-820, 2009
54. Ravindranath MH, Kaneku H, El-Awar N, Morales-Buenrostro LE, Terasaki PI: Antibodies to HLA-E in nonalloimmunized males: Pattern of HLA-Ia reactivity of anti-HLA-E-positive sera. J Immunol 185: 1935-1948, 2010
55. Ravindranath MH, Taniguchi M, Chen CW, Ozawa M, Kaneku H, El-Awar N, Cai J, Terasaki PI: HLA-E monoclonal antibodies recognize shared peptide sequences on classical HLA class Ia: Relevance to human natural HLA antibodies. Mol Immunol 47: 1121-1131, 2010
56. Zachary AA, Lucas DP, Detrick B, LeffellMS: Naturally occurring interference in Luminex assays for HLA-specific antibodies: Characteristics and resolution. Hum Immunol 70: 496-501, 2009
57. Masson E, DevillardN, Chabod J, Yannaraki M, Thevenin C, Tiberghien P, Rebibou JM: Misleading de novo detection of serum anti-HLA-A3 antibodies in kidney recipients having received ATG before transplantation. Hum Immunol 71: 170-175, 2010
58. Gloor JM, Moore SB, Schneider BA, Degoey SR, Stegall MD: The effect of antithymocyte globulin on anti-human leukocyte antigen antibody detection assays. Transplantation 84: 258-264, 2007
59. Breitenbach C, Kaelin L, Chapman P, Gebel HM, Bray RA: 8-P: Pretreatment of patient serumwith fetal bovine serum(FBS) reduces non-specific background and enhances HLA antibody detection in bead and cell based assays. Hum Immunol 74[Suppl]: 57, 2013
60. Cai J, Terasaki PI, Anderson N, Lachmann N, Schönemann C: Intact HLA not beta2mfree heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation 88: 226-230, 2009
61. Pereira S, Perkins S, Lee JH, Shumway W, LeFor W, Lopez-Cepero M, Wong C, Connolly A, Tan JC, Grumet FC: Donorspecific antibody against denatured HLAA1: Clinically nonsignificant? HumImmunol 72: 492-498, 2011
62. Gombos P, Opelz G, Scherer S, Morath C, Zeier M, Schemmer P, Susal C: Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Am J Transplant 13: 2075-2082, 2013
63. Morales-Buenrostro LE, Terasaki PI, Marino-Vázquez LA, Lee JH, El-Awar N, Alberú J: "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 86: 1111-1115, 2008
64. El-Awar N, Terasaki PI, Nguyen A, Sasaki N, Morales-Buenrostro LE, Saji H, Maruya E, Poli F: Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol 70: 844-853, 2009
65. Poli F, Benazzi E, Innocente A, Nocco A, Cagni N,Gianatti A, Fiocchi R, ScalamognaM: Heart transplantation with donor-specific antibodies directed toward denatured HLA-A∗02: 01: A case report. Hum Immunol 72: 1045-1048, 2011
66. GandhiMJ, Carrick DM, Jenkins S, De Goey S, Ploeger NA, Wilson GA, Lee JH, Winters JL, Stubbs JR, Toy P, Norris PJ; National Heart, Lung, and Blood Institute Specialized Center of Clinically Oriented Research TRALI Study and Retrovirus Epidemiology Donor Study-II: Lot-to-lot variability in HLA antibody screening using a multiplexed bead-based assay. Transfusion 53: 1940-1947, 2013
67. Friedlander R, Putheti P, Diaz E, Menon A, Ponce B,Muthukumar T, Sharma VK, Dadhania D, SuthanthiranM:On the detection of anti-HLA antibodies using single antigen bead Luminex assay: Lot-to-lot variations in MFI. Transplantation 96: e24-e26, 2013
68. Gebel HM, Bray RA, Nickerson P: Pretransplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 3: 1488-1500, 2003
69. Kerman RH, Susskind B, Buyse I, Pryzbylowski P, Ruth J, Warnell S, Gruber SA, Katz S, Van Buren CT, Kahan BD: Flow cytometrydetected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation 68: 1855-1858, 1999
70. Lonze BE, Dagher NN, Simpkins CE, Locke JE, Singer AL, Segev DL, Zachary AA, Montgomery RA: Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant 10: 2154-2160, 2010
71. Marfo K, Lu A, Ling M, Akalin E: Desensitization protocols and their outcome. Clin J Am Soc Nephrol 6: 922-936, 2011
72. Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, Zachary AA, Segev DL: Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 365: 318-326, 2011
73. Reinsmoen NL, Lai CH, Vo A, Cao K,Ong G, Naim M, Wang Q, Jordan SC: Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 86: 820-825, 2008
74. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC: Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359: 242-251, 2008
75. Vo AA, Petrozzino J, Yeung K, Sinha A, Kahwaji J, Peng A, Villicana R,Mackowiak J, Jordan SC: Efficacy, outcomes, and costeffectiveness of desensitization using IVIG and rituximab. Transplantation 95: 852-858, 2013
76. Weston M, Rolfe M, Haddad T, Lopez-Cepero M: Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants. Clin Transpl 2009: 393-399, 2009
77. Zachary AA, Montgomery RA, Leffell MS: Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum Immunol 66: 364-370, 2005
78. Jordan SC, Tyan D, Stablein D,McIntosh M, Rose S, Vo A, ToyodaM, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J: Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J AmSocNephrol 15: 3256-3262, 2004
79. Bentall A, Cornell LD, Gloor JM, Park WD, Gandhi MJ, Winters JL, Chedid MF, Dean PG, Stegall MD: Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 13: 76-85, 2013
80. Gloor JM, Winters JL, Cornell LD, Fix LA, DeGoey SR, Knauer RM, Cosio FG, Gandhi MJ, Kremers W, Stegall MD: Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 10: 582-589, 2010
81. Higgins R, Lowe D,HathawayM, WilliamsC, Lam FT, Kashi H, Tan LC, Imray C, Fletcher S, Chen K, Krishnan N, Hamer R, Daga S, Edey M, Zehnder D, Briggs D: Human leukocyte antigen antibody-incompatible renal transplantation: Excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation 92: 900-906, 2011
82. Caro-Oleas JL, González-Escribano MF, González-Roncero FM, Acevedo-Calado MJ, Cabello-Chaves V, Gentil-Govantes MA, Núñez-Roldán A: Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephrol Dial Transplant 27: 1231-1238, 2012
83. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, Gautreau C, Charron D, Glotz D, Suberbielle-Boissel C: Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 21: 1398-1406, 2010
84. Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, Briley KP, Haisch CE, Bolin P, Parker K, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI: The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 95: 1113-1119, 2013
85. Zeevi A, Lunz J, Feingold B, Shullo M, Bermudez C, Teuteberg J, Webber S: Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant 32: 98-105, 2013
86. Crespo M, Torio A, Mas V, Redondo D, Pérez-Sáez MJ, Mir M, Faura A, Guerra R, Montes-Ares O, Checa MD, Pascual J: Clinical relevance of pretransplant anti-HLA donor-specific antibodies: Does C1q-fixation matter? Transpl Immunol 29: 28-33, 2013
87. HöngerG,WahrmannM, Amico P, Hopfer H, Böhmig GA, Schaub S: C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 89: 1471-1475, 2010
88. Dunn TB, Noreen H, Gillingham K, Maurer D, Ozturk OG, Pruett TL, Bray RA, Gebel HM, Matas AJ: Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 11: 2132-2143, 2011
89. Ishida H, Hirai T, Kohei N, Yamaguchi Y, Tanabe K: Significance of qualitative and quantitative evaluations of anti-HLA antibodies in kidney transplantation. Transpl Int 24: 150-157, 2011
90. Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S: Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 87: 1681-1688, 2009
91. Riethmüller S, Ferrari-Lacraz S, Müller MK, Raptis DA, Hadaya K, Rüsi B, Laube G, Schneiter G, Fehr T, Villard J: Donor-specific antibody levels and three generations of crossmatches topredict antibody-mediatedrejection in kidney transplantation. Transplantation 90: 160-167, 2010
92. GibneyEM,CagleLR, FreedB,Warnell SE,Chan L, Wiseman AC: Detection of donor-specific antibodies using HLA-coated microspheres: Another tool for kidney transplant risk stratification. Nephrol Dial Transplant 21: 2625-2629, 2006
93. Eng HS, Bennett G, Tsiopelas E, Lake M, Humphreys I, Chang SH, Coates PT, Russ GR: Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 8: 2335-2342, 2008
94. Otten HG, Verhaar MC, Borst HP, Hene RJ, van Zuilen AD: Pretransplant donor-specific HLA class-I and-II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 12: 1618-1623, 2012
95. Singh N, Djamali A, Lorentzen D, Pirsch JD, Leverson G,Neidlinger N, Voss B, Torrealba JR, Hofmann RM, Odorico J, Fernandez LA, Sollinger HW, Samaniego M: Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 90: 1079-1084, 2010
96. SicardA,Amrouche L,Suberbielle C,Carmagnat M, Candon S, Thervet E, Delahousse M, Legendre C, Chatenoud L, Snanoudj R: Outcome of kidney transplantations performed with preformed donor-specific antibodies of unknown etiology.AmJ Transplant 14: 193-201, 2014
97. Couzi L, Araujo C, Guidicelli G, Bachelet T, Moreau K, Morel D, Robert G,Wallerand H, Moreau JF, Taupin JL, Merville P: Interpretation of positive flow cytometric crossmatch in the era of the single-antigen bead assay. Transplantation 91: 527-535, 2011
98. Aubert V, Venetz JP, Pantaleo G, PascualM: Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 70: 580-583, 2009
99. Vlad G, Ho EK, Vasilescu ER, Colovai AI, Stokes MB, Markowitz GS, D'Agati VD, Cohen DJ, Ratner LE, Suciu-Foca N: Relevance of different antibody detection methods for the prediction of antibodymediated rejection and deceased-donor kidney allograft survival. Hum Immunol 70: 589-594, 2009
100. Süsal C, Ovens J, Mahmoud K, Döhler B, Scherer S, Ruhenstroth A, Tran TH, Heinold A, Opelz G: No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: A Collaborative Transplant Study report. Transplantation 91: 883-887, 2011
101. Orandi BJ, Garonzik-Wang JM, Massie AB, Zachary AA, Montgomery JR, Van Arendonk KJ, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Nelson PW, Wellen J, Bozorgzadeh A, Gaber AO, Montgomery RA, Segev DL: Quantifying the risk of incompatible kidney transplantation: A multicenter study. Am J Transplant 14: 1573-1580, 2014
102. Opelz G, Terasaki PI: Recipient selection for renal retransplantation. Transplantation 21: 483-488, 1976
103. Opelz G; Collaborative Transplant Study: Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 365: 1570-1576, 2005
104. Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II: The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: Short waiting time and excellent graft outcome. Transplantation 78: 190-193, 2004
105. Montgomery RA, Gentry SE, Marks WH, Warren DS, Hiller J, Houp J, Zachary AA, MelanconJK,MaleyWR, RabbH, SimpkinsC, SegevDL:Domino paired kidney donation: A strategy tomake best use of live non-directed donation. Lancet 368: 419-421, 2006
106. Montgomery RA, Zachary AA, Ratner LE, Segev DL, Hiller JM, Houp J, Cooper M, Kavoussi L, Jarrett T, Burdick J, Maley WR, Melancon JK, Kozlowski T, Simpkins CE, PhillipsM, Desai A, Collins V, Reeb B, Kraus E, Rabb H, Leffell MS, Warren DS: Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. JAMA 294: 1655-1663, 2005
107. Bingaman AW, Wright FH Jr., Kapturczak M, Shen L, Vick S, Murphey CL: Single-center kidney paired donation: The Methodist San Antonio experience.AmJ Transplant 7: 626-632, 2012
108. de Klerk M, Weimar W: Ingredients for a successful living donor kidney exchange program. Transplantation 86: 511-512, 2008
109. Terasaki PI, Ozawa M: Predicting kidney graft failure by HLA antibodies: A prospective trial. Am J Transplant 4: 438-443, 2004
110. Terasaki PI, Ozawa M: Predictive value of HLA antibodies and serum creatinine in chronic rejection: Results of a 2-year prospective trial. Transplantation 80: 1194-1197, 2005
111. Worthington JE, Martin S, Al-Husseini DM, Dyer PA, Johnson RW: Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 75: 1034-1040, 2003
112. Piazza A, Poggi E, Ozzella G, Borrelli L, Scornajenghi A, Iaria G, Tisone G, Adorno D: Post-transplant donor-specific antibody production and graft outcome in kidney transplantation: Results of sixteen-year monitoring by flow cytometry. Clin Transpl 2006: 323-336, 2006
113. Fotheringham J, Angel C, Goodwin J, Harmer AW,McKaneWS: Natural history of proteinuria in renal transplant recipients developing de novo human leukocyte antigen antibodies. Transplantation 91: 991-996, 2011
114. Everly MJ, Rebellato LM, Haisch CE,Ozawa M, Parker K, Briley KP, Catrou PG, Bolin P, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI: Incidence and impact of de novo donor-specific alloantibody inprimary renal allografts. Transplantation 95: 410-417, 2013
115. de Kort H, Willicombe M, Brookes P, Dominy KM, Santos-Nunez E, Galliford JW, Chan K, Taube D, McLean AG, Cook HT, Roufosse C: Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant 13: 485-492, 2013
116. Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, Goldberg A, Birk PE, Rush DN, Nickerson PW: Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 12: 1157-1167, 2012
117. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB: Complementfixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 16: 12-17, 2012
118. Ginevri F, Nocera A, Comoli P, Innocente A, Cioni M, Parodi A, Fontana I, Magnasco A, NoccoA, TagliamaccoA, SementaA,Ceriolo P, Ghio L, Zecca M, Cardillo M, Garibotto G, Ghiggeri GM, Poli F: Posttransplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibodymediated rejection. Am J Transplant 12: 3355-3362, 2012
119. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB: C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 91: 342-347, 2011
120. Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC: Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 91: 1103-1109, 2011
121. Hidalgo LG,Campbell PM, Sis B, EineckeG, Mengel M, Chang J, Sellares J, Reeve J, Halloran PF: De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 9: 2532-2541, 2009
122. Scornik JC, Guerra G, Schold JD, Srinivas TR, Dragun D, Meier-Kriesche HU: Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant 7: 1808-1814, 2007
123. Lachmann N, Terasaki PI, Schönemann C: Donor-specific HLA antibodies in chronic renal allograft rejection: A prospective trial with a four-year follow-up. Clin Transpl 2006: 171-199, 2006
124. Hourmant M, Cesbron-Gautier A, Terasaki PI, Mizutani K, Moreau A, Meurette A, Dantal J, Giral M, Blancho G, Cantarovich D, Karam G, Follea G, Soulillou JP, Bignon JD: Frequency and clinical implications of development of donor-specific and nondonor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 16: 2804-2812, 2005
125. Liefeldt L, Brakemeier S, Glander P, Waiser J, Lachmann N, Schonemann C, Zukunft B, Illigens P, Schmidt D, Wu K, Rudolph B, Neumayer HH, Budde K: Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 12: 1192-1198, 2012
126. DeVos JM, Gaber AO, Knight RJ, Land GA, SukiWN, Gaber LW, Patel SJ: Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 82: 598-604, 2012
127. Cardarelli F, Pascual M, Tolkoff-Rubin N, Delmonico FL, Wong W, Schoenfeld DA, ZhangH,Cosimi AB, Saidman SL: Prevalence and significance of anti-HLA and donorspecific antibodies long-term after renal transplantation. Transpl Int 18: 532-540, 2005
128. Mizutani K, Terasaki P, Rosen A, Esquenazi V, Miller J, ShihRN, Pei R,OzawaM, Lee J: Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 5: 2265-2272, 2005
129. Campos EF, Tedesco-Silva H, Machado PG, Franco M, Medina-Pestana JO, Gerbase-DeLima M: Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 6: 2316-2320, 2006
130. Lee PC, Zhu L, Terasaki PI, Everly MJ: HLAspecific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 88: 568-574, 2009
131. Li X, Ishida H, Yamaguchi Y, Tanabe K: Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation. Transpl Int 21: 1145-1152, 2008.
132. DörjeC,MidtvedtK,Holdaas H, NaperC, Strøm EH,ØyenO, Leivestad T, Aronsen T, Jenssen T, Flaa-Johnsen L, Lindahl JP, Hartmann A, Reisæter AV: Early versus late acute antibodymediated rejection in renal transplant recipients. Transplantation 96: 79-84, 2013
133. Everly MJ, Rebellato LM, Ozawa M, Briley KP, Catrou PG, Haisch CE, Terasaki PI: Beyond histology: Lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation 89: 962-967, 2010
134. Walsh RC, Brailey P, Girnita A, Alloway RR, Shields AR, Wall GE, Sadaka BH, Cardi M, Tevar A, Govil A, Mogilishetty G, Roy-Chaudhury P, Woodle ES: Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 91: 1218-1226, 2011
135. Everly MJ, Everly JJ, Arend LJ, Brailey P, Susskind B, Govil A, Rike A, Roy-Chaudhury P, Mogilishetty G, Alloway RR, Tevar A, Woodle ES: Reducing de novo donorspecific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 9: 1063-1071, 2009
136. Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D, Suberbielle-Boissel C: Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibodymediated rejection. Am J Transplant 9: 1099-1107, 2009
137. Willicombe M, Brookes P, Sergeant R, Santos-Nunez E, Steggar C, Galliford J, McLean A, CookTH,CairnsT,RoufosseC,TaubeD:Denovo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 94: 172-177, 2012
138. Amico P, Hönger G, Bielmann D, Lutz D, Garzoni D, Steiger J, Mihatsch MJ, Dragun D, Schaub S: Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies. Transplantation 85: 1557-1563, 2008
139. Terasaki PI, Ozawa M, Castro R: Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 7: 408-415, 2007
140. Lemy A, Andrien M, Lionet A, Labalette M, Noel C, Hiesse C, Delahousse M, Suberbielle-Boissel C, DeMeyer M, Latinne D,MouradM, Delsaut S, Racapé J, Wissing KM, Toungouz M, Abramowicz D: Posttransplant major histocompatibility complex class I chain-related gene A antibodies and long-term graft outcomes in a multicenter cohort of 779 kidney transplant recipients. Transplantation 93: 1258-1264, 2012
141. Giral M, Foucher Y, Dufay A, Van Huyen JP, Renaudin K, Moreau A, Philippe A, Hegner B, Dechend R, Heidecke H, Brouard S, Cesbron A, Castagnet S, Devys A, Soulillou JP, Dragun D: Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant 13: 2567-2576, 2013
142. Taniguchi M, Rebellato LM, Cai J, Hopfield J, Briley KP, Haisch CE, Catrou PG, Bolin P, Parker K, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI: Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant 13: 2577-2589, 2013
143. Flechner SM, Fatica R, Askar M, Stephany BR, Poggio E, Koo A, Banning S, Chiesa-Vottero A, Srinivas T: The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 90: 1486-1492, 2010
144. Wiebe C, Nickerson P: Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation. Curr Opin Organ Transplant 18: 470-477, 2013
145. Wiebe C, Pochinco D, Blydt-Hansen TD, Ho J, Birk PE, Karpinski M, Goldberg A, Storsley LJ, Gibson IW, Rush DN, Nickerson PW: Class II HLA epitope matching-A strategy to minimize de novo donorspecific antibody development and improve outcomes. Am J Transplant 13: 3114-3122, 2013
146. Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF: Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence.AmJ Transplant 12: 388-399, 2012
147. Katerinis I, Hadaya K, Duquesnoy R, Ferrari-Lacraz S, Meier S, van Delden C, Martin PY, Siegrist CA, Villard J: De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant 11: 1727-1733, 2011
148. Locke JE, Zachary AA, Warren DS, Segev DL, Houp JA, Montgomery RA, Leffell MS: Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant 9: 2136-2139, 2009
149. Takemoto S, Terasaki PI, Gjertson DW, Cecka JM: Equitable allocation of HLAcompatible kidneys for local pools and minorities. N Engl J Med 331: 760-764, 1994
150. McKenna RM, Lee KR, Gough JC, Jeffery JR, Grimm PC, Rush DN, Nickerson P: Matching for private or publicHLA epitopes reduces acute rejection episodes and improves two-year renal allograft function. Transplantation 66: 38-43, 1998